Drug Profile
Mupirocin foam
Alternative Names: MupiFoam; Topical mupirocin - FoamixLatest Information Update: 16 Mar 2020
Price :
$50
*
At a glance
- Originator Foamix
- Class Antibacterials; Carboxylic acids; Epoxy compounds; Esters; Nonanoic acids; Pyrans; Skin disorder therapies; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Skin and soft tissue infections
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 30 Aug 2005 Mupirocin foam is available for licensing (http://www.foamix.co.il)
- 30 Aug 2005 Phase-II clinical trials in Skin and soft tissue infections in Israel (Topical)